Stockscreener 앱 받기
0.00
100.00%
-29.08
시간 외 거래:
29.30
29.30
+
전일 마감가:
$29.08
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$145.36M
수익:
$34.77M
순이익/손실:
$-74.04M
주가수익비율:
0.00
EPS:
-8.0157
순현금흐름:
$-79.76M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$30.39
52주 변동 폭
$0.00
$30.39
Mersana Therapeutics Inc Stock (MRSN) Company Profile
명칭
Mersana Therapeutics Inc
전화
617-498-0020
주소
840 MEMORIAL DRIVE, CAMBRIDGE
MRSN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
0.00 | 145.36M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | William Blair | Outperform |
| 2024-11-15 | 재개 | Citigroup | Buy |
| 2024-03-19 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-29 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-02-29 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-07-28 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-07-27 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-27 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-07-27 | 다운그레이드 | Truist | Buy → Hold |
| 2023-07-27 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-06-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-06-15 | 개시 | Guggenheim | Buy |
| 2023-03-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-20 | 개시 | Citigroup | Buy |
| 2022-11-21 | 개시 | Truist | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-08-30 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | Credit Suisse | Neutral |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-04-29 | 개시 | BTIG Research | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-11 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-11-14 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-05-08 | 개시 | Robert W. Baird | Outperform |
| 2018-03-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
Mersana Therapeutics Inc 주식(MRSN)의 최신 뉴스
Is Mersana Therapeutics Inc. stock a buy on dips2025 Market Outlook & Technical Pattern Based Signals - ulpravda.ru
Is Mersana Therapeutics Inc. stock a buy before product launches2025 Technical Overview & AI Powered Trade Plan Recommendations - ulpravda.ru
Will Mersana Therapeutics Inc. stock maintain growth storyWeekly Trade Report & Fast Gain Stock Tips - ulpravda.ru
How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance
Day One concludes Mersana Therapeutics acquisition - Yahoo Finance
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics By Investing.com - Investing.com Nigeria
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Mersana Therapeutics Completes Merger and Delists from Nasdaq - TipRanks
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Mersana Therapeutics Announced Transfer or Voluntary Withdrawal of Listing - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
Mersana Therapeutics, Inc.(NasdaqGS: MRSN) dropped from S&P TMI Index - MarketScreener
Panic Selling: Is Mersana Therapeutics Inc stock positioned for long term growthWeekly Risk Report & AI Driven Stock Reports - moha.gov.vn
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSEALEX), United Security Bancshares (NasdaqUBFO), Udemy, Inc. (NasdaqUDMY), Mersana Therapeutics, Inc. (Nasdaq - GlobeNewswire Inc.
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
MRSN (Mersana Therapeutics) EV-to-OCF : -1.23 (As of Dec. 22, 2025) - GuruFocus
Fund Flows: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Fed Impact & Weekly High Conviction Trade Ideas - Улправда
Is Mersana Therapeutics Inc. stock trading at a premium valuationJuly 2025 Decliners & Intraday High Probability Setup Alerts - Улправда
What insider trading reveals about Mersana Therapeutics Inc. stockWeekly Stock Report & Free Community Supported Trade Ideas - Улправда
Mersana Therapeutics Earnings Notes - Trefis
Will Mersana Therapeutics Inc. stock maintain momentum in 2025July 2025 EndofMonth & High Win Rate Trade Alerts - DonanımHaber
How Mersana Therapeutics Inc. stock performs in interest rate cyclesQuarterly Market Summary & Real-Time Buy Zone Alerts - Улправда
Mersana Therapeutics, Inc.(NasdaqGS: MRSN) dropped from NASDAQ Biotechnology Index - marketscreener.com
Is Mersana Therapeutics Inc. stock cheap compared to fundamentals2025 Market WrapUp & Verified High Yield Trade Plans - Улправда
How Mersana Therapeutics Inc. (0M4) stock compares with market leaders2025 Earnings Impact & Real-Time Volume Analysis - Улправда
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights - Sahm
Shareholder Alert: The Ademi Firm continues to investigate wheth - GuruFocus
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Luminus Management LLC Sells 989,314 Shares of Mersana Therapeutics, Inc. $MRSN - MarketBeat
Why Analysts See Mersana’s Story Shifting To Deal And CVR Outcomes After $1B Buyout - Yahoo Finance
Halper Sadeh LLC Encourages FFWM, MRSN, FSUN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
683 Capital Management LLC Boosts Stock Position in Mersana Therapeutics, Inc. $MRSN - MarketBeat
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc.MRSN - PR Newswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
News - FinancialContent
Why The Narrative Around Day One Biopharmaceuticals Is Shifting After The Mersana Acquisition - Yahoo Finance
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-SMLR, MRSN, CDTX, and RYI - The Malaysian Reserve
Day One Biopharmaceuticals Expands with Mersana Acquisition - StocksToTrade
Is Mersana Therapeutics Inc 0M4 a good long term investmentLarge Cap Stability Picks & High Return Trading Ideas - earlytimes.in
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—SMLR, MRSN, CDTX, and RYI - Morningstar
Mersana Therapeutics (MRSN) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal - MSN
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Is Mersana Therapeutics Inc. (0M4) stock prepared for digital transitionRate Hike & Daily Growth Stock Investment Tips - Newser
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarter - Newser
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - Newser
Why Mersana Therapeutics Inc. (0M4) stock could be next leaderJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How Mersana Therapeutics Inc. (0M4) stock compares with top peersQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsJuly 2025 Review & Consistent Income Trade Ideas - Newser
Mersana Therapeutics Inc (MRSN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):